- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02956785
What After the First Propess (PRODUCT)
What After the First Propess. A Randomised Comparative Prospective Study
Study Overview
Status
Conditions
Detailed Description
This randomized study will be carried out at delivery suite in Warwick Hospital after eligible women have been informed of the study when booked for induction of labor and provided with the study information leaflet
When attending for induction of labor on delivery suite, an informed consent will be obtained then all women will have a cardiotocogram (CTG) performed initially and will be assessed by vaginal examination and Bishop score recorded at insertion of first slow-release pessary (Propess®10 mg Dinoprostone; CTS, UK), which will be inserted high into the posterior vaginal fornix. Assessment and insertion of pessary will be done by an experienced obstetrician or a senior midwife
All women will be given the required care and support as per the local protocols and guidelines
Women will be excluded from the study within the first 24 hours of induction of labor in the following conditions:
- Women with abnormal or non-reassuring CTG needing intervention.
- Women needing tocolytic use.
- Women needing removal of the Dinoprostone pessary.
- Women needing emergency Caesarean section.
- If spontaneous rupture of membranes occurs.
- If artificial rupture of membranes is achievable after the first 24 hours of induction of labor (Bishop score 5 or more)
- If woman withdraws her consent to continue as a part of the study.
After 24 hours from insertion of the first Dinoprostone pessary, women will be reassessed and a total of 330 women with Bishop score less than 7, will be randomly assigned to one of three intervention groups by a pre-formed computer-generated random list and randomization put in sealed opaque envelopes kept in a locked secure area on delivery suite.
Intervention groups will be as follows:
Group 1 (110 women):
Women will have the initial slow-release Dinoprostone pessary left in place for six more hours (total of 30 hours in place) then removed followed by vaginal assessment 48 hours after the start of labour induction and insertion of a second slow-release pessary if required (Currently Propess® is not licensed to be repeated as a second dose. However, there is a consensus that, the dose may be repeated after a consultant review and an informed verbal consent as per SWH 00190 Induction and Augmentation of the First and Second Stage of Labour Management Guideline, 2012).
Group 2 (110 women):
Women will have the initial slow-release Dinoprostone pessary removed followed by insertion of quick-release Dinoprostone tablet (Prostin® 3 mg Dinoprostone vaginal tablet; Pfizer, UK) high in the posterior vaginal fornix immediately after removal of the slow-release pessary. The tablet will be left for 6 hours followed by vaginal reassessment and insertion of a second tablet if ARM is still not achievable.
Group 3 (110 women):
Women will have the initial slow-release Dinoprostone pessary removed followed by insertion of 1-5 Osmotic cervical rods (Dilapan-S® Aquacryl hydrogel rod; HPSRx Enterprises, USA) by a senior obstetrician or a midwife into the cervical canal, immediately after removal of the slow-release pessary using a vaginal speculum and a holder. The rods will be left for 12-24 hours.
For all participants, after achieving spontaneous or artificial rupture of membranes, the local protocol for intrapartum care will be followed and after delivery, the women will be asked to fill in a patient's satisfaction questionnaire about the process of induction, care given and being a part of the study
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Walsall, United Kingdom, WS2 9PS
- Walsall Healthcare NHS Trust
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Women booked for induction of labor at 37 to 42 weeks gestation
- Viable singleton pregnancy.
- Cephalic presentation.
- Intact membranes.
- No previous Caesarean section.
- No antenatal fetal concerns (Fetal growth restriction (FGR), small for gestational age (SGA), impaired Doppler, oligohydramnios, non-reassuring/abnormal CTG).
Exclusion Criteria:
- Pregnancy less than completed 37 weeks or more than 42 weeks.
- Multiple pregnancy.
- Intrauterine fetal death.
- Non-cephalic presentation.
- Pre-labor rupture of membranes
- Previous one or more Caesarean sections.
- Antenatal concerns regarding fetal well-being (FGR, SGA, impaired Doppler, oligohydramnios, non-reassuring/abnormal CTG).
- Non-reassuring or abnormal CTG on admission to labor ward
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Extension of propess+/-second propess
Women will have the initial slow-release Dinoprostone pessary left in place for six more hours (total of 30 hours in place) then removed followed by vaginal assessment 48 hours after the start of labour induction and insertion of a second slow-release pessary if required
|
Other Names:
|
Active Comparator: Prostin
Women will have the initial slow-release Dinoprostone pessary removed followed by insertion of quick-release Dinoprostone tablet (Prostin® 3 mg Dinoprostone vaginal tablet; Pfizer, UK) high in the posterior vaginal fornix immediately after removal of the slow-release pessary.
The tablet will be left for 6 hours followed by vaginal reassessment and insertion of a second tablet if ARM is still not achievable.
|
Other Names:
|
Active Comparator: Dilapan-S
Women will have the initial slow-release Dinoprostone pessary removed followed by insertion of 1-5 Osmotic cervical rods (Dilapan-S® Aquacryl hydrogel rod; HPSRx Enterprises, USA) by a senior obstetrician or a midwife into the cervical canal, immediately after removal of the slow-release pessary using a vaginal speculum and a holder.
The rods will be left for 12-24 hours.
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of achieving spontaneous or artificial rupture of membranes
Time Frame: 12 months
|
percentage of women who will have spontaneous or artificial rupture of membranes
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time interval needed from start of induction of labor to achieve spontaneous or artificial rupture of membranes
Time Frame: 12 months
|
The time frame is 6 months from the onset of the study till assessing the results, doing the analysis and presenting. But, the time interval stated as an outcome here is the period of time elapsing from starting induction of labour and rupturing the membranes whether spontaneous or artificial |
12 months
|
Rate of hyperstimulation (contractions more than 5 in 10 minutes or each contraction lasting more than 90 seconds)
Time Frame: 12 months
|
percentage of women who will develop uterine hyperstimulation
|
12 months
|
Rate of abnormal CTG changes needing intervention
Time Frame: 12 months
|
percentage of women with non-reassuring or abnormal CTG that need intervention
|
12 months
|
Rate of need for tocolysis
Time Frame: 12 months
|
percentage of women who need tocolysis to treat hyperstimulation
|
12 months
|
Rate of emergency Caesarean section
Time Frame: 12 months
|
percentage of women who need Caesarean section for fetal distress or failed induction/progress of labour
|
12 months
|
Grades of Caesarean sections
Time Frame: 12 months
|
percentage of each of grade 1,2 and 3 Caesarean sections among each group
|
12 months
|
Women's satisfaction with the method of induction used
Time Frame: 12 months
|
scoring system based on women's questionnaire formed of 3 questions with a score of 3 to 15.
In addition, evaluation of pain score out of 10
|
12 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Amr H Farag, Consultant, Walsall Healthcare NHS Trust
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 202984
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Induction of Labor
-
Holy Family Hospital, Nazareth, IsraelNot yet recruitingInduction of LaborIsrael
-
Kazakhstan's Medical University "KSPH"Asfendiyarov Kazakh National Medical UniversityActive, not recruitingInduction of LaborKazakhstan
-
Sorlandet Hospital HFOstfold Hospital Trust; Haukeland University Hospital; St. Olavs Hospital; Nordlandssykehuset...Completed
-
Cairo UniversityMohamed El Sharkawy; Yomna Bayoumi; mohamed hisham gouda; Dina latifCompleted
-
Christian Medical College and Hospital, Ludhiana...Completed
-
Christiana Care Health ServicesCompletedInduction of LaborUnited States
-
Assistance Publique - Hôpitaux de ParisAgence Nationale de sécurité du MédicamentCompleted
-
Icahn School of Medicine at Mount SinaiCompleted
-
University of California, San FranciscoCompletedInduction of LaborUnited States
-
Rambam Health Care CampusNot yet recruitingInduction of Labor
Clinical Trials on 10 mg Dinoprostone; CTS, UK
-
Intermountain Health Care, Inc.Ferring PharmaceuticalsTerminatedInduction of Labor Affected Fetus / NewbornUnited States
-
Clinical Hospital MerkurCompletedInduction of Labor Affected Fetus / Newborn | Prostaglandins Causing Adverse Effects in Therapeutic UseCroatia
-
University of OklahomaFerring PharmaceuticalsCompletedInduction of Labor | Cervical RipeningUnited States
-
Università degli Studi dell'InsubriaCompletedCervical Ripening | Labor InductionItaly
-
Cairo UniversityCompletedIntrauterine DeviceEgypt
-
Ferring PharmaceuticalsCompletedLabor, Induced | Cervical RipeningUnited States, Canada
-
National University of MalaysiaRecruitingMedical; Abortion, Fetus | Missed Abortion | Incomplete AbortionMalaysia
-
Merck Sharp & Dohme LLCCompleted